Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Banking Press Releases.
Press releases published on October 18, 2025
Nasdaq Halts Platinum Analytics Cayman Limited
NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Platinum Analytics Cayman Limited (Nasdaq: PLTS) for additional information requested from the company. Previously, the Securities and …
BexBack Launches No KYC, 100x Leverage, and $50 Welcome Bonus for Easy Crypto Futures Trading!
SINGAPORE, Oct. 18, 2025 (GLOBE NEWSWIRE) -- BexBack Exchange has launched an aggressive new promotion to empower both new and seasoned crypto traders: All eligible new users receive a $50 welcome bonus and a 100% deposit bonus match. As the crypto market …
Astra Bitcoin: Dr. Antoun Toubia Launches a Revolutionary Asset-Backed Ecosystem Built on Ethereum
TBILISI, Georgia, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Astra Bitcoin officially debuts as a new force in digital finance — a blockchain ecosystem where real-world assets meet decentralized innovation. Founded by Dr. Antoun Toubia, a renowned figure in wealth …
NUTX 3-DAY DEADLINE ALERT: Nutex Health (NUTX) Faces Investor Lawsuit Over Alleged Revenue Inflation Scheme-- Hagens Berman
SAN FRANCISCO, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a …
VRA Investor News: If You Have Suffered Losses in Vera Bradley, Inc. (NASDAQ: VRA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera Bradley, Inc. (NASDAQ: VRA) resulting from allegations that Vera …
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) …
Reconstruction and Opportunities: The CDFG Consumer White Paper 2024-2025 is Released
Reconstruction and Opportunities: The CDFG Consumer White Paper 2024-2025 is Released Reconstruction and Opportunities: The CDFG Consumer White Paper 2024-2025 is Released Source: CDFG Consumer White Paper 2024-2025 Source: CDFG Consumer White Paper 2024- …
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolled Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median …
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc …
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and in 11.5% of patients treated with …
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib’s potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors 50% …
Blazpay’s Phase 2 of Crypto Presale Surges With Over $250,000 Raised as XRP and Bitcoin Consolidate
PANAMA CITY , Oct. 18, 2025 (GLOBE NEWSWIRE) -- The crypto market is buzzing this week as investors weigh the latest developments in Bitcoin, XRP, and emerging AI-powered projects. Bitcoin remains relatively stable, trading between $109,655 and $111,844 …
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients In the 120 mg palazestrant cohort among patients with prior …
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUC CRB-701 continues to demonstrate a favorable safety and tolerability profile Registrational studies planned to start in mid-2026 Company to host an HNSCC KOL event …
Aeroméxico Announces Filing of Amended Registration Statement for Proposed Global Offering
MEXICO CITY, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Grupo Aeroméxico, S.A.B. de C.V. (“Aeroméxico”) today announced the launch of its global offering (the “Global Offering”), consisting of 11,727,325 American Depositary Shares (“ADSs”) in the United States and …
rYojbaba Expands Core Consulting and Health Services Business Internationally Through Partnerships with Koyamada International Foundation and Guardian Girls International
FUKUOKA, Japan, Oct. 17, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, announced a series of strategic corporate developments and global partnerships to …